SCHEMBL3257717

SCHEMBL3257717

Cc1cccc(CCC(=O)N2CCN(c3nc(C(C)(C)C)ns3)CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MC4R P32245 1/20 0.46
▸ FAAH O00519 2/20 0.43
▸ POLB P06746 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ HTT P42858 1/20 0.41
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ TPSAB1 Q15661 1/20 0.40
▸ TPSD1 Q9BZJ3 1/20 0.40
▸ TPSG1 Q9NRR2 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ CASP3 P42574 1/20 0.40
▸ CASP7 P55210 1/20 0.40
▸ ME2 P23368 1/20 0.39
▸ ME1 P48163 1/20 0.39
▸ ME3 Q16798 1/20 0.39
▸ USP2 O75604 1/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ GFER P55789 1/20 0.39
▸ MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3257719 0.82 FAAH (0.45) FAAHPOLBALDH1A1NPC1RAB9A
SCHEMBL3254042 0.81 FAAH (0.54) MC4RFAAHNPC1RAB9AL3MBTL1
SCHEMBL3259383 0.80 MC4R (0.47) MC4RPOLBALDH1A1HTTNPC1
SCHEMBL3259324 0.77 ALDH1A1 (0.48) MC4RPOLBALDH1A1HTTRAB9A
SCHEMBL10196665 0.74 POLB (0.73) POLBALDH1A1HTTNPC1RAB9A
SCHEMBL27951770 0.73 FAAH (0.62) FAAHNPC1RAB9A
SCHEMBL4907919 0.72 MEN1 (0.65) ALDH1A1KMT2AMEN1MAPT
SCHEMBL3257953 0.70 KMT2A (0.54) POLBALDH1A1NPC1RAB9AL3MBTL1
SCHEMBL2007241 0.67 GFER (0.61) FAAHPOLBALDH1A1NPC1RAB9A
SCHEMBL3150793 0.66 GRM5 (0.40) POLBALDH1A1HTTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765816-B1 SUBSTITUTED 1-PROPIOLYLPIPERAZINES HAVING AN AFFINITY FOR THE MGLUR5 RECEPTOR IN ORDER TO TREAT PAINFUL CONDITIONS GRUENENTHAL GMBH (DE) 2010-03-10 — — EP claimed
US-7300939-B2 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-11-27 — — US claimed
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-05-17 — — US claimed
EP-1765816-B1 SUBSTITUTED 1-PROPIOLYLPIPERAZINES HAVING AN AFFINITY FOR THE MGLUR5 RECEPTOR IN ORDER TO TREAT PAINFUL CONDITIONS GRUENENTHAL GMBH (DE) 2010-03-10 — — EP disclosed
US-7300939-B2 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-11-27 — — US disclosed
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRM5, GRIK5, GRM1 MC4R 703/4885FAAH 771/4885POLB 4235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback